Mometasone-Teva spray nasal suspension 50μg/dose 10g (60 dose) — Made in Czech Republic — Free Delivery

The use of the preparation in young children should be carried out with the help of adults.

The preparation should not be used in the presence of untreated local infection with involvement of the nasal mucosa in the process.

The preparation Mometasone-Teva should be used with caution or not at all in patients with active or latent tuberculosis infection of the respiratory tract, as well as in untreated fungal, bacterial, systemic viral infections.

In patients using GCS, immunity can potentially be suppressed, and they should be warned of the increased risk of infection through contact with persons with certain infectious diseases (such as chickenpox, measles), as well as the need to consult a doctor if such contact takes place.

After 12 months of treatment with mometasone furoatom, there were no signs of atrophy of the nasal mucosa; in addition, mometasone furoate contributed to the normalization of the histological picture of the nasal mucosa. As with any long-term treatment, patients who have been using the preparation  for several months or longer should be periodically examined to identify possible changes in the nasal mucosa. In the event of the development of a local fungal infection of the nose or pharynx, it may be necessary to discontinue preparation therapy or conduct appropriate treatment. Irritation of the nasal and pharyngeal mucosa, which persists for a long time, may also be an indication for discontinuation of treatment.

The use of the preparation Mometasone-Teva is not recommended in the case of the development of perforation of the nasal septum.

In clinical studies, the incidence of nosebleeds was higher compared with placebo. Epistaxis was generally mild and stopped spontaneously.

Mometasone-Teva contains benzalkonium chloride as a preservative, which may cause nasal irritation.

Systemic effects of nasal corticosteroids may occur, in particular when high doses are used, intended for long-term use. These manifestations occur much less frequently than with the use of oral corticosteroids, they can be different in different patients and when taking different corticosteroids. Potential systemic effects may include Cushing's syndrome, cushingoid traits, suppression of adrenal function, growth retardation in children and adolescents, cataracts, glaucoma, and, less commonly, a number of psychological or behavioral effects, in particular psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (in especially in children).

After the use of intranasal corticosteroids, cases of increased intraocular pressure have been reported.

Patients switching to nasal spray treatment after prolonged therapy with systemic corticosteroids should be carefully monitored. Discontinuation of systemic corticosteroids in these patients may cause adrenal insufficiency. If these patients show signs and symptoms of adrenal insufficiency or withdrawal syndrome (for example, joint and / or muscle pain, fatigue and depression), despite the disappearance of nasal symptoms, the use of systemic corticosteroids should be resumed along with other treatments and appropriate measures taken. With such a transition, pre-existing allergic conditions, such as allergic conjunctivitis and eczema, may also appear, the manifestation of which was previously suppressed by therapy with systemic GCS. With long-term treatment with Mometasone-Teva, there were no signs of suppression of the function of the hypothalamic-pituitary-adrenal system.

The use of doses in excess of the recommended ones can provoke clinically significant adrenal suppression. If there is evidence of the use of doses exceeding the recommended ones during periods of stress or planned operations, the likelihood of using additional systemic GCS should be considered.

The safety and efficacy of Mometasone-Teva when used to treat unilateral polyps, polyps associated with cystic fibrosis, or polyps that completely cover the nasal cavity have not been studied.

For unilateral polyps that have an unusual or asymmetrical appearance, especially with ulcers and bleeding, further evaluation is necessary.

It is recommended to regularly measure the height of children receiving long-term treatment with nasal corticosteroids. If growth is slowed down, therapy should be revised in order to reduce the dose of nasal corticosteroids, if possible, to the minimum dose at which effective control of symptoms is maintained. In addition, the patient should be referred to a pediatrician for consultation.

Although the preparation controls nasal symptoms in most patients, the simultaneous use of appropriate concomitant therapy can lead to an additional reduction in the severity of other symptoms, in particular from the eye.